Fuyuhiko Tamanoi

Fuyuhiko Tamanoi's AcademicInfluence.com Rankings

Fuyuhiko Tamanoi

Chemistry

#4220

World Rank

#5286

Historical Rank

Inorganic Chemistry

#227

World Rank

#241

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Fuyuhiko Tamanoi's Degrees

PhD Chemistry University of Tokyo

Why Is Fuyuhiko Tamanoi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Fuyuhiko Tamanoi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. (2008) (1539)
Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. (2010) (917)
Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. (2007) (911)
The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae (1990) (637)
Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. (2010) (530)
Light-activated nanoimpeller-controlled drug release in cancer cells. (2008) (412)
Spatial regulation of the exocyst complex by Rho1 GTPase (2001) (339)
Differential activation of yeast adenylate cyclase by wild type and mutant RAS proteins (1985) (307)
A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. (2004) (301)
IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein. (1990) (284)
Analysis of the transforming potential of the human H-ras gene by random mutagenesis. (1984) (255)
Identification of Ras farnesyltransferase inhibitors by microbial screening. (1993) (241)
Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy (2010) (224)
Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. (2011) (212)
Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. (2015) (207)
Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. (2010) (206)
In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. (2012) (198)
Rho3 of Saccharomyces cerevisiae, Which Regulates the Actin Cytoskeleton and Exocytosis, Is a GTPase Which Interacts with Myo2 and Exo70 (1999) (198)
Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein* (2009) (198)
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer (2010) (196)
The Rheb family of GTP-binding proteins. (2004) (195)
Loss of the TOR Kinase Tor2 Mimics Nitrogen Starvation and Activates the Sexual Development Pathway in Fission Yeast (2007) (191)
Therapeutic intervention based on protein prenylation and associated modifications (2006) (172)
Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells (2007) (168)
Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin (1998) (164)
RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer* (2001) (163)
Drosophila Rheb GTPase is required for cell cycle progression and cell growth (2003) (163)
Inhibitors of Ras farnesyltransferases. (1993) (159)
The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. (1995) (149)
Small-molecule inhibitors of protein geranylgeranyltransferase type I. (2007) (148)
Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells (2007) (147)
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells (2002) (145)
pH-Operated mechanized porous silicon nanoparticles. (2011) (136)
Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. (2016) (131)
The Saccharomyces cerevisiae Rheb G-protein Is Involved in Regulating Canavanine Resistance and Arginine Uptake* (2000) (128)
Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. (1998) (126)
Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines (2000) (120)
Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. (2013) (119)
Identification of Dominant Negative Mutants of Rheb GTPase and Their Use to Implicate the Involvement of Human Rheb in the Activation of p70S6K* (2003) (118)
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. (2013) (112)
Common modifications of trimeric G proteins and ras protein: involvement of polyisoprenylation. (1990) (112)
Purification of an adenovirus-coded DNA polymerase that is required for initiation of DNA replication (1982) (112)
Systematic Identification of Cellular Signals Reactivating Kaposi Sarcoma–Associated Herpesvirus (2007) (111)
Protein geranylgeranyltransferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product but not the DPR1 gene product. (1991) (109)
Patterned Hexagonal Arrays of Living Cells in Sol−Gel Silica Films (2000) (107)
Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene (1996) (105)
Two-photon-triggered drug delivery via fluorescent nanovalves. (2014) (104)
IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase-activating protein. (1991) (101)
Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. (2009) (101)
Function of adenovirus terminal protein in the initiation of DNA replication. (1982) (100)
Yeast CAL1 is a structural and functional homologue to the DPR1 (RAM) gene involved in ras processing. (1991) (99)
Two-photon-triggered drug delivery in cancer cells using nanoimpellers. (2013) (95)
Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast (2005) (93)
Differential Requirement of CAAX-mediated Posttranslational Processing for Rheb Localization and Signaling (2009) (91)
Processing and fatty acid acylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. (1986) (91)
Mevalonate Pathway and Human Cancers. (2017) (88)
Mutants of Saccharomyces cerevisiae defective in the farnesylation of Ras proteins. (1990) (88)
Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin (2010) (86)
Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells (2001) (81)
Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control (2008) (80)
Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. (1994) (79)
Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation (2004) (78)
A novel yeast mutant defective in the processing of ras proteins: assessment of the effect of the mutation on processing steps. (1987) (77)
Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer (2018) (77)
Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds* (2008) (75)
In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I (2009) (72)
A product of yeast RAS2 gene is a guanine nucleotide binding protein. (1984) (70)
Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant (2001) (70)
Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. (2016) (70)
Farnesylated proteins and cell cycle progression (2001) (70)
The Schizosaccharomyces pombe cwg2+ gene codes for the beta subunit of a geranylgeranyltransferase type I required for beta‐glucan synthesis. (1993) (69)
Activating mutations of TOR (target of rapamycin) (2011) (69)
Silica nanoparticles as a delivery system for nucleic acid-based reagents. (2009) (68)
Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. (2018) (67)
Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. (2017) (67)
Mutation of a termination codon affects src initiation (1984) (64)
A novel approach to tag and identify geranylgeranylated proteins (2009) (64)
Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. (2015) (63)
Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase (2012) (62)
The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. (1991) (62)
Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress (2006) (61)
Mechanism of DNA chain growth. XI. Structure of RNA-linked DNA fragments of Escherichia coli. (1973) (61)
AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. (2008) (60)
Initiation of adenovirus DNA replication in vitro requires a specific DNA sequence. (1983) (59)
Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. (2012) (58)
DNA sequences required for the in vitro replication of adenovirus DNA. (1984) (56)
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways (2005) (55)
Site of linkage between adenovirus type 12 and cell DNAs in hamster tumour line CLAC3 (1981) (55)
Ras signaling in yeast. (2011) (55)
Amino Acid Substitutions That Convert the Protein Substrate Specificity of Farnesyltransferase to That of Geranylgeranyltransferase Type I* (1997) (54)
Recent progress in the study of the Rheb family GTPases. (2014) (53)
Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. (2001) (52)
Structure and expression of yeast DPR1, a gene essential for the processing and intracellular localiation of ras proteins (1988) (50)
Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. (2015) (48)
The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast (2008) (47)
RAS2 protein of Saccharomyces cerevisiae undergoes removal of methionine at N terminus and removal of three amino acids at C terminus. (1990) (46)
GapIII, a new brain‐enriched member of the GTPase‐activating protein family (1995) (46)
Purified yeast protein farnesyltransferase is structurally and functionally similar to its mammalian counterpart. (1993) (46)
Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. (1998) (46)
The TSC/Rheb/TOR Signaling Pathway in Fission Yeast and Mammalian Cells: Temperature Sensitive and Constitutive Active Mutants of TOR (2007) (45)
Significance of filamin A in mTORC2 function in glioblastoma (2015) (44)
IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein (1990) (44)
Tailoring the biodegradability of porous silicon nanoparticles. (2012) (43)
Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. (2008) (42)
Uracil incorporation into nascent DNA of thymine-requiring mutant of Bacillus subtilis 168. (1978) (42)
Protein Farnesylation Is Critical for Maintaining Normal Cell Morphology and Canavanine Resistance in Schizosaccharomyces pombe * (2000) (42)
PAK1 Kinase Promotes Cell Motility and Invasiveness through CRK-II Serine Phosphorylation in Non-Small Cell Lung Cancer Cells (2012) (41)
Nucleotide sequence of the primary origin of bacteriophage T7 DNA replication: relationship to adjacent genes and regulatory elements. (1980) (41)
A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors* (1999) (40)
Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. (2014) (40)
Physical mapping of primary and secondary origins of bacteriophage T7 DNA replication. (1980) (40)
Replication of bacteriophage T7 DNA by purified proteins. (1979) (39)
Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. (2016) (38)
Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes (1994) (36)
The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner* (2009) (34)
S-farnesylation and methyl esterification of C-terminal domain of yeast RAS2 protein prior to fatty acid acylation. (1991) (34)
C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. (1996) (33)
Molecular targets and the treatment of myeloid leukemia. (2006) (33)
Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles (1996) (33)
Terminal region recognition factor 1, a DNA-binding protein recognizing the inverted terminal repeats of the pGKl linear DNA plasmids. (1991) (33)
Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues (2019) (32)
Initiation of DNA replication at the primary origin of bacteriophage T7 by purified proteins: requirement for T7 RNA polymerase. (1981) (31)
Posttranslational modification of ras proteins: Detection of a modification prior to fatty acid acylation and cloning of a gene responsible for the modification (1988) (30)
The origin of adenovirus DNA replication. (1984) (29)
Characterization of the geranylgeranyl transferase type I from Schizosaccharomyces pombe (1998) (29)
In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells (2013) (28)
Kir, a novel Ras-family G-protein, induces invasive pseudohyphal growth in Saccharomyces cerevisiae. (1995) (26)
Fighting cancer by disrupting C-terminal methylation of signaling proteins. (2004) (25)
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis (2015) (25)
Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy (2019) (24)
Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter (2014) (24)
Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape (2021) (24)
Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. (2012) (24)
Rheb Protein Binds CAD (Carbamoyl-phosphate Synthetase 2, Aspartate Transcarbamoylase, and Dihydroorotase) Protein in a GTP- and Effector Domain-dependent Manner and Influences Its Cellular Localization and Carbamoyl-phosphate Synthetase (CPSase) Activity* (2014) (24)
Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase (1997) (24)
Characterization of Rheb functions using yeast and mammalian systems. (2001) (24)
Mutant farnesyltransferase beta subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I beta subunit. (1995) (23)
Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. (2018) (23)
Cytosolic and mitochondrial ROS production resulted in apoptosis induction in breast cancer cells treated with Crocin: The role of FOXO3a, PTEN and AKT signaling. (2020) (23)
Rheb G-Proteins and the Activation of mTORC1. (2010) (23)
A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. (2017) (23)
Prenylation of RAS and Inhibitors of Prenyltransferases (1996) (22)
Anticancer Effect and Molecular Targets of Saffron Carotenoids. (2014) (21)
Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle‐Based Anticancer Drug (2020) (21)
Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications (2019) (20)
Phosphorylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. (1989) (20)
Molecular machines involved in protein transport across cellular membranes (2007) (19)
Energy coupling and molecular motors (2004) (17)
A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity (1992) (17)
Characterization of the Raptor/4E-BP1 Interaction by Chemical Cross-linking Coupled with Mass Spectrometry Analysis* (2014) (17)
A novel metal-chelating inhibitor of protein farnesyltransferase. (2003) (16)
Identification and Characterization of Mechanism of Action of P61-E7, a Novel Phosphine Catalysis-Based Inhibitor of Geranylgeranyltransferase-I (2011) (16)
Impact of Pore–Walls Ligand Assembly on the Biodegradation of Mesoporous Organosilica Nanoparticles for Controlled Drug Delivery (2018) (14)
How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth? (2015) (14)
Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. (2013) (13)
Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase-activating proteins. (1994) (13)
The Ras superfamily G-proteins. (2013) (12)
Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. (2018) (12)
Adenoviral DNA replication: DNA sequences and enzymes required for initiation in vitro. (1983) (12)
Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures (2019) (12)
Drug Release from Three‐Dimensional Cubic Mesoporous Silica Nanoparticles Controlled by Nanoimpellers (2014) (12)
Persistence of RNA attached to nascent short DNA pieces in Bacillus subtilis cells defective in DNA polymerase I. (1977) (11)
Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women’s breast cancer tumors (2018) (11)
Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy (2020) (11)
Use of yeast two-hybrid system to evaluate Ras interactions with neurofibromin-GTPase-activating protein. (1995) (11)
Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy (2021) (10)
New activated RAS2 mutations identified in Saccharomyces cerevisiae. (1993) (10)
Eukaryotic RNases and their partners in RNA degradation and biogenesis (2012) (9)
In vitro delivery of calcium ions by nanogated mesoporous silica nanoparticles to induce cancer cellular apoptosis (2017) (9)
Cloning of the T7 genome in Escherichia coli: use of recombination between cloned sequences and bacteriophage T7 to identify genes involved in recombination and a clone containing the origin of T7 DNA replication. (1979) (9)
Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. (1995) (9)
Uracil incorporation into nascent DNA of Bacillus subtilis and Escherichia coli. (1979) (9)
Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy (2020) (9)
Structure, function and regulation of TOR complexes from yeasts to mammals (2010) (8)
On the Mechanism of Adenovirus DNA Replication (1986) (8)
Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast. (2010) (8)
Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction. (2006) (7)
Natural products and cancer signaling : isoprenoids, polyphenols and flavonoids (2014) (7)
Chemical Biology / Chemical Genetics / Chemical Genomics : Importance of Chemical Library (2008) (7)
A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. (2013) (6)
[5] In vivo assays for farnesyltransferase inhibitors with Saccharomyces cereuisiae (1995) (6)
Reducing particle size of biodegradable nanomaterial for efficient curcumin loading (2020) (6)
Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells (2015) (6)
An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation (2018) (6)
mTOR Signaling and Human Cancer (2010) (5)
Phosphatidylinositol 5-phosphate 4-kinase (2012) (5)
Facile synthesis of biodegradable mesoporous functionalized-organosilica nanoparticles for enhancing the anti-cancer efficiency of cordycepin (2021) (5)
The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine (2021) (5)
Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. (2009) (4)
Mechanism of the anticancer effect of phytochemicals (2015) (4)
Tuning the Biodegradability of Silicon Nanoparticles for Drug Delivery (2013) (4)
Initiation ofadenovirus DNA replication invitro requires aspecific DNA sequence (1983) (4)
Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray (2021) (4)
Reconstitution of yeast farnesyltransferase from individually purified subunits. (1999) (4)
Recent excitements in the study of the CAM assay. (2019) (4)
Inhibitors of the Ras superfamily G-proteins (2013) (4)
Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy (2012) (4)
Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. (2017) (4)
Abstract LB-9: Light-controllable nano-drug delivery system with deep tissue penetrating ability for cancer therapy with two-photon-triggered nanoimpellers (2014) (3)
Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. (2018) (3)
Fiber-Optic Based Laser Wakefield Accelerated Electron Beams and Potential Applications in Radiotherapy Cancer Treatments (2022) (3)
Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. (2006) (3)
3 Mutational analyses of protein farnesyltransferase (2001) (3)
In vivo assays for farnesyltransferase inhibitors with Saccharomyces cerevisiae. (1995) (3)
INITIATION OF BACTERIOPHAGE T7 DNA REPLICATION (1981) (2)
Chapter 7 - Small-Molecule Inhibitors of GGTase-I from the Heterocycle Library Derived from Phosphine Catalysis (2011) (2)
[Rheb-mTOR signaling pathway involved in tumor formation]. (2010) (2)
Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. (2018) (2)
A genetic approach to the study of farnesylation (1990) (2)
Inhibitors of the Ras superfamily of small G-proteins. Preface. (2013) (2)
Phosphorylation of RAS 1 and RAS 2 proteins in Saccharomyces cerevisiae (2)
Signaling pathways in plants (2014) (2)
Abstract A09: Therapeutic targeting of TSC2-deficient cells with Methotrexate: Results of a drug repurposing screen (2017) (1)
Convergence of the Study on Monochromatic X-rays and the Research on Nanoparticles Opens Up a Possibility to Develop a New Type of Radiation Therapy (2020) (1)
Functional Significance ofLysine 1423ofNeurofibromin and Characterization ofa SecondSiteSuppressor WhichRescues Mutations atThisResidue andSuppresses (1994) (1)
Engineering Biodegradable Periodic Mesoporous Functionalized-Organosilica Nanocarriers for Efficient Paclitaxel Delivery (2022) (1)
Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model (2022) (1)
Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors (2001) (1)
Analysis of cell–nanoparticle interactions and imaging of in vitro labeled cells showing barcorded endosomes using fluorescent thiol-organosilica nanoparticles surface-functionalized with polyethyleneimine (2022) (1)
The small molecule compound, MCP1, inhibits Ras-Raf interaction in mammalian cells and induces apoptosis in various hematopoietic cancer cells (2004) (1)
Characterization of the Raptor / 4 EBP 1 Interaction by Chemical Cross-linking Coupled with Mass Spectrometry Analysis * (2014) (1)
In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells (2013) (1)
Coupled with Mass Spectrometry Analysis Interaction by Chemical Cross-linking Characterization of the Raptor/4E-BP1 (2014) (1)
Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells (2001) (1)
A Novel Metal‐Chelating Inhibitor of Protein Farnesyltransferase. (2003) (1)
Platelet-activating factor acetylhydrolases (PAF-AH) (2015) (1)
ID: 4001 Nanoparticle-based Cancer Therapy (2017) (0)
[Recombinant DNA technology and its use in the study of adenovirus]. (1982) (0)
Protein farnesyltransferase, alpha subunit (2009) (0)
Abstract A36: Interruption of K-Ras/PAK1/Crk pathway has a dramatic anti-tumor effect in NSCLC (2014) (0)
mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin (2022) (0)
Analysis of the transforming potential of the human Hras gene by random mutagenesis ( oncogenes / in vitro mutagenesis / gene transfer ) (0)
PTPe (RPTPe and Cyt-PTPe) (2012) (0)
Welcome to CRRM2017 (2017) (0)
Abstract LB-243: Discovery of single amino acid changes that confer constitutive activation of mTOR in human cancer (2010) (0)
Abstract 2702: The mTOR complex 2-associated interactome and cell migration ability determination in brain cancers (2018) (0)
Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy (2021) (0)
The enzymes second edition part 2. (2022) (0)
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis (2015) (0)
Development of New Targeted Boronated Small Molecule Drugs for Boron Neutron Capture Therapy (BNCT) (2022) (0)
Inhibition of DNA synthesis and cancer therapies. (2022) (0)
An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation (2018) (0)
Abstract 3906: Characterization of mTORC2 interactome reveals association with microtubules in glioblastoma and neuroblastoma cells (2022) (0)
Abstract 4535: The mTOR complex 2 promotes glioblastoma migration via the interactions with multiple actin-binding and microtubule-associated proteins (2019) (0)
Abstract 1670: Characterization of the chick chorioallantoic membrane tumor model in comparison with various xenograft mouse tumors (2020) (0)
Correction to: Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy (2021) (0)
2 Sec Protein-Conducting Channel and SecA (2018) (0)
Extended characterization of MCP110, an inhibitor of Ras-dependent signaling: Mode of action and preclinical analysis (2004) (0)
Abstract POSTER-THER-1426: Characterization and targeting of TWIST family proteins to prevent chemoresistance and metastasis in ovarian cancer (2015) (0)
Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy (2023) (0)
Chips : 98 % Sensitivity and Specificity (2016) (0)
Significance of filamin A in mTORC2 function in glioblastoma (2015) (0)
Ras Family G-Proteins in Saccharomyces Cerevisiae and Schizosaccharomyces Pombe (2006) (0)
The Interaction of Proteins and DNA Sequences Required for Adenovirus DNA Replication in-Vitro (1983) (0)
TITLE : A Genetic Approach to Define the Importance of Rheb in Tuberous Sclerosis PRINCIPAL INVESTIGATOR : (2006) (0)
Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer (2018) (0)
Synthesis of various phosphodiesters and phosphomonoesters with ribonuclease N. (1976) (0)
“Nanotechnology Cancer Asia-Pacific (NCAP) Network” was launched (2012) (0)
Studies of Protein Farnesylation in Yeast (2007) (0)
10.19 – Smart-Drug Delivery and Target-Specific Therapy (2014) (0)
11 - Global Analysis of Prenylated Proteins by the Use of a Tagging via Substrate Approach (2011) (0)
Abstract 2152: Optimizing therapies for drug-resistant ovarian cancer stem cells using aCAM-PDX model (2018) (0)
[Function of ras oncogene product]. (1985) (0)
Abstract P2-07-04: Treatment of metastatic breast cancer using two nanoparticles combined with siRNA targeting Twist1 to inhibit EMT (2015) (0)
The enzymes first edition. (2022) (0)
A Genetic Approach to Define the Importance of Rheb in Tuberous Sclerosis (2006) (0)
Summary of volume 51: DNA damage and double-strand breaks. (2022) (0)
Controllable drug delivery by light-activated nanoimpellers for cancer therapy (2008) (0)
Mutant farnesyltransferase subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I (2005) (0)
Post-Translational Modification of ras Proteins: Palmitoylation and Phosphorylation of Yeast ras Proteins (1989) (0)
[Recent developments in targeted therapy for cancers and drug discovery]. (2014) (0)
Overview of DNA damage and double-strand breaks. (2022) (0)
Targeted and Controlled Release of Anticancer Drugs using Novel Nanoparticles (2015) (0)
PCAF Lysine Acetyltransferase (2008) (0)
The enzymes second edition part 1. (2022) (0)
ID: 1062 The chicken egg tumor model provides an attractive system for evaluating anticancer drugs (2017) (0)
PC-1 (Human) (2012) (0)
Auger electrons and DNA double-strand breaks studied by using iodine-containing chemicals. (2022) (0)
Abstract 219: Identification of the mechanistic target of rapamycin complex 2-associated interactome involved in brain cancer cell motility by affinity purification-mass spectrometry (2017) (0)
Psk 1 , an AGC kinase family member in fission yeast , is directly phosphorylated and controlled by TORC 1 as S 6 kinase (2012) (0)
A product of yeast RAS 2 gene is a guanine nucleotide binding protein ( oncogenes / evolution ) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Fuyuhiko Tamanoi?

Fuyuhiko Tamanoi is affiliated with the following schools:

Hiroshima University
Kanazawa University
Kobe University
University of Tokyo
University of California, Los Angeles
University of Chicago
Nagoya University
Kyoto University